schliessen

Filtern

 

Bibliotheken

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

BACKGROUNDThe National Institute for Health and Care Excellence (NICE) has issued multiple guidance for the first-line management of patients with lung cancer and recommends different combinations of chemotherapy treatments. This review provides a synthesis of clinical effectiveness and cost-effecti... Full description

Journal Title: Health technology assessment (Winchester England), July 2013, Vol.17(31), pp.1-278
Main Author: Brown, T
Other Authors: Pilkington, G , Bagust, A , Boland, A , Oyee, J , Tudur-Smith, C , Blundell, M , Lai, M , Martin Saborido, C , Greenhalgh, J , Dundar, Y , Dickson, R
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 2046-4924 ; DOI: 10.3310/hta17310
Link: http://search.proquest.com/docview/1413163125/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1413163125
title: Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
format: Article
creator:
  • Brown, T
  • Pilkington, G
  • Bagust, A
  • Boland, A
  • Oyee, J
  • Tudur-Smith, C
  • Blundell, M
  • Lai, M
  • Martin Saborido, C
  • Greenhalgh, J
  • Dundar, Y
  • Dickson, R
subjects:
  • Antineoplastic Combined Chemotherapy Protocols–Economics
  • Carcinoma, Non-Small-Cell Lung–Therapeutic Use
  • Carcinoma, Squamous Cell–Drug Therapy
  • Clinical Trials As Topic–Pathology
  • Cost-Benefit Analysis–Pathology
  • Erbb Receptors–Genetics
  • Humans–Drug Therapy
  • Lung Neoplasms–Pathology
  • Neoplasm Metastasis–Pathology
  • Quality-Adjusted Life Years–Pathology
  • Erbb Receptors
ispartof: Health technology assessment (Winchester, England), July 2013, Vol.17(31), pp.1-278
description: BACKGROUNDThe National Institute for Health and Care Excellence (NICE) has issued multiple guidance for the first-line management of patients with lung cancer and recommends different combinations of chemotherapy treatments. This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. OBJECTIVESTo evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently licensed in Europe and recommended by NICE, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). DATA SOURCESThree electronic databases (MEDLINE, EMBASE and The Cochrane Library) were searched from 2001 to August 2010. REVIEW METHODSTrials that compared first-line chemotherapy currently licensed in Europe and recommended by NICE in chemotherapy-naive adult patients with locally advanced or metastatic NSCLC were included. Data on key outcomes including, but not limited to, overall survival (OS), progression-free...
language: eng
source:
identifier: E-ISSN: 2046-4924 ; DOI: 10.3310/hta17310
fulltext: fulltext
issn:
  • 20464924
  • 2046-4924
url: Link


@attributes
ID1210837484
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1413163125
sourceidproquest
recordidTN_proquest1413163125
sourcesystemPC
pqid1413163125
display
typearticle
titleClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
creatorBrown, T ; Pilkington, G ; Bagust, A ; Boland, A ; Oyee, J ; Tudur-Smith, C ; Blundell, M ; Lai, M ; Martin Saborido, C ; Greenhalgh, J ; Dundar, Y ; Dickson, R
contributorBrown, T (correspondence author) ; Brown, T (record owner)
ispartofHealth technology assessment (Winchester, England), July 2013, Vol.17(31), pp.1-278
identifierE-ISSN: 2046-4924 ; DOI: 10.3310/hta17310
subjectAntineoplastic Combined Chemotherapy Protocols–Economics ; Carcinoma, Non-Small-Cell Lung–Therapeutic Use ; Carcinoma, Squamous Cell–Drug Therapy ; Clinical Trials As Topic–Pathology ; Cost-Benefit Analysis–Pathology ; Erbb Receptors–Genetics ; Humans–Drug Therapy ; Lung Neoplasms–Pathology ; Neoplasm Metastasis–Pathology ; Quality-Adjusted Life Years–Pathology ; Erbb Receptors
descriptionBACKGROUNDThe National Institute for Health and Care Excellence (NICE) has issued multiple guidance for the first-line management of patients with lung cancer and recommends different combinations of chemotherapy treatments. This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. OBJECTIVESTo evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently licensed in Europe and recommended by NICE, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). DATA SOURCESThree electronic databases (MEDLINE, EMBASE and The Cochrane Library) were searched from 2001 to August 2010. REVIEW METHODSTrials that compared first-line chemotherapy currently licensed in Europe and recommended by NICE in chemotherapy-naive adult patients with locally advanced or metastatic NSCLC were included. Data on key outcomes including, but not limited to, overall survival (OS), progression-free...
languageeng
source
version4
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1413163125/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Brown, T
1Pilkington, G
2Bagust, A
3Boland, A
4Oyee, J
5Tudur-Smith, C
6Blundell, M
7Lai, M
8Martin Saborido, C
9Greenhalgh, J
10Dundar, Y
11Dickson, R
titleClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
descriptionBACKGROUNDThe National Institute for Health and Care Excellence (NICE) has issued multiple guidance for the first-line management of patients with lung cancer and recommends different combinations of chemotherapy treatments. This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. OBJECTIVESTo evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently licensed in Europe and recommended by NICE, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). DATA SOURCESThree electronic databases (MEDLINE, EMBASE and The Cochrane Library) were searched from 2001 to August 2010. REVIEW METHODSTrials that compared first-line chemotherapy currently licensed in Europe and recommended by NICE in chemotherapy-naive adult patients with locally advanced or metastatic NSCLC were included. Data on key outcomes including, but not limited to, overall survival (OS), progression-free...
subject
0Antineoplastic Combined Chemotherapy Protocols–Economics
1Carcinoma, Non-Small-Cell Lung–Therapeutic Use
2Carcinoma, Squamous Cell–Drug Therapy
3Clinical Trials As Topic–Pathology
4Cost-Benefit Analysis–Pathology
5Erbb Receptors–Genetics
6Humans–Drug Therapy
7Lung Neoplasms–Pathology
8Neoplasm Metastasis–Pathology
9Quality-Adjusted Life Years–Pathology
10Erbb Receptors
general
0English
110.3310/hta17310
2MEDLINE (ProQuest)
3ProQuest Biological Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
11Biological Science Index (ProQuest)
sourceidproquest
recordidproquest1413163125
issn
020464924
12046-4924
rsrctypearticle
creationdate2013
addtitleHealth technology assessment (Winchester, England)
searchscope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
scope
01007527
11007944
21009130
310000004
410000038
510000050
610000120
710000159
810000238
910000253
1010000260
1110000270
1210000271
1310000302
1410000350
15proquest
lsr43
01007527false
11007944false
21009130false
310000004false
410000038false
510000050false
610000120false
710000159false
810000238false
910000253false
1010000260false
1110000270false
1210000271false
1310000302false
1410000350false
contributorBrown, T
startdate20130701
enddate20130701
citationpf 1 pt 278 vol 17 issue 31
lsr30VSR-Enriched:[date, pqid, issn]
sort
titleClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
authorBrown, T ; Pilkington, G ; Bagust, A ; Boland, A ; Oyee, J ; Tudur-Smith, C ; Blundell, M ; Lai, M ; Martin Saborido, C ; Greenhalgh, J ; Dundar, Y ; Dickson, R
creationdate20130701
lso0120130701
facets
frbrgroupid7844135044574930768
frbrtype5
newrecords20181218
languageeng
creationdate2013
topic
0Antineoplastic Combined Chemotherapy Protocols–Economics
1Carcinoma, Non-Small-Cell Lung–Therapeutic Use
2Carcinoma, Squamous Cell–Drug Therapy
3Clinical Trials As Topic–Pathology
4Cost-Benefit Analysis–Pathology
5Erbb Receptors–Genetics
6Humans–Drug Therapy
7Lung Neoplasms–Pathology
8Neoplasm Metastasis–Pathology
9Quality-Adjusted Life Years–Pathology
10Erbb Receptors
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Natural Science Collection
3ProQuest SciTech Collection
4Biological Science Database
5Natural Science Collection
6SciTech Premium Collection
7Health Research Premium Collection
8Health Research Premium Collection (Alumni edition)
9Biological Science Index (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Brown, T
1Pilkington, G
2Bagust, A
3Boland, A
4Oyee, J
5Tudur-Smith, C
6Blundell, M
7Lai, M
8Martin Saborido, C
9Greenhalgh, J
10Dundar, Y
11Dickson, R
jtitleHealth technology assessment (Winchester, England)
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Brown
1Pilkington
2Bagust
3Boland
4Oyee
5Tudur-Smith
6Blundell
7Lai
8Martin Saborido
9Greenhalgh
10Dundar
11Dickson
aufirst
0T
1G
2A
3J
4C
5M
6Y
7R
au
0Brown, T
1Pilkington, G
2Bagust, A
3Boland, A
4Oyee, J
5Tudur-Smith, C
6Blundell, M
7Lai, M
8Martin Saborido, C
9Greenhalgh, J
10Dundar, Y
11Dickson, R
addauBrown, T
atitleClinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
jtitleHealth technology assessment (Winchester, England)
risdate20130701
volume17
issue31
spage1
epage278
pages1-278
eissn2046-4924
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDThe National Institute for Health and Care Excellence (NICE) has issued multiple guidance for the first-line management of patients with lung cancer and recommends different combinations of chemotherapy treatments. This review provides a synthesis of clinical effectiveness and cost-effectiveness evidence supporting current guidance. OBJECTIVESTo evaluate the clinical effectiveness and cost-effectiveness of first-line chemotherapy currently licensed in Europe and recommended by NICE, for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). DATA SOURCESThree electronic databases (MEDLINE, EMBASE and The Cochrane Library) were searched from 2001 to August 2010. REVIEW METHODSTrials that compared first-line chemotherapy currently licensed in Europe and recommended by NICE in chemotherapy-naive adult patients with locally advanced or metastatic NSCLC were included. Data on key outcomes including, but not limited to, overall survival (OS), progression-free...
doi10.3310/hta17310
urlhttp://search.proquest.com/docview/1413163125/
issn13665278
date2013-07